{
  "symbol": "REGN",
  "year": 2022,
  "period": "Q1",
  "competition_summary": [
    {
      "competitor": "Development Risks \u2022 Drug",
      "mentions": 1,
      "context": "competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates. \u2022 We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad. Regulatory and Development Risks \u2022 Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consumi"
    },
    {
      "competitor": "Intellectual Property and Market Exclusivity Risks \u2022",
      "mentions": 1,
      "context": "competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates. \u2022 We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad. Regulatory and Development Risks \u2022 Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consumi"
    }
  ]
}